QTTB's EPS dropped in early 2024 due to increased research and development expenses, which led to a net loss of $14.2 million for the quarter. However, this was a significant improvement from the $27.1 million loss in the same period the previous year1. The company's focus on advancing its clinical programs and the completion of enrollment in its Phase 2 clinical trials may have contributed to the increased expenses2.